ClinicalTrials.Veeva

Menu

Genetic Basis of Mitral Valve Prolapse (MVP)

Mass General Brigham logo

Mass General Brigham

Status

Enrolling

Conditions

Mitral Valve Prolapse

Study type

Observational

Funder types

Other

Identifiers

NCT01719211
1999-p-007948

Details and patient eligibility

About

The investigators have successfully identified two novel genetic loci for MVP on chromosomes 11 and 13 and are searching for altered genes in these regions. This requires recruiting large families who may have MVP linked to these or other chromosomes; and obtaining DNA samples from 1,000-1,500 individually affected patients to study the relation between DNA markers throughout the genome and MVP. It is our expectation that the results of this study will lead to the discovery of gene(s) responsible for MVP. This will lead to improved understanding of the disease and, in turn, improved ability to treat and prevent progression in genetically susceptible individuals.

Full description

This is a genome-wide association study.

Enrollment

1,500 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Mitral valve prolapse

Exclusion criteria

  • Other mitral valve diseases

Trial contacts and locations

1

Loading...

Central trial contact

Susan Slaugenhaupt, PhD; Robert a levine, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems